Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Kate Kelley

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics|April 25, 2019
Emerging Role for Systemic Therapy in Earlier Stages of HCCRobin Kate Kelley
Clinical Advances in Hematology & Oncology : H&O|December 5, 2022
The evolving role of combination systemic therapies in hepatocellular carcinomaRobin Kate Kelley
Gastroenterology & Hepatology|November 18, 2022
The Evolving Role of Combination Systemic Therapies in Hepatocellular CarcinomaRobin Kate Kelley
The Lancet. Oncology|October 5, 2015
Adjuvant sorafenib for liver cancer: wrong stage, wrong doseRobin Kate Kelley
Gastroenterology & Hepatology|February 28, 2024
Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular CarcinomaRobin Kate Kelley
Journal of Gastrointestinal Oncology|August 9, 2019
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature reviewAudra N Boscoe, Catherine Rolland, Robin Kate Kelley
Clinical Liver Disease|April 1, 2020
Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular CarcinomaLaura A Huppert, John D Gordan, Robin Kate Kelley
Journal of Hepatology|January 20, 2020
Systemic therapies for intrahepatic cholangiocarcinomaRobin Kate Kelley, John Bridgewater, Gregory J Gores, et al.
Cancer Treatment Reviews|May 24, 2021
Cabozantinib: An evolving therapy for hepatocellular carcinomaAnthony B El-Khoueiry, Diana L Hanna, Josep Llovet, et al.
JAMA Ophthalmology|October 24, 2024
Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for CholangiocarcinomaIsabell Kassaye, Adam Alyafaie, Karen Zhang, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|April 25, 2019
Emerging Role for Systemic Therapy in Earlier Stages of HCCRobin Kate Kelley
Clinical Advances in Hematology & Oncology : H&O|December 5, 2022
The evolving role of combination systemic therapies in hepatocellular carcinomaRobin Kate Kelley
Gastroenterology & Hepatology|November 18, 2022
The Evolving Role of Combination Systemic Therapies in Hepatocellular CarcinomaRobin Kate Kelley
The Lancet. Oncology|October 5, 2015
Adjuvant sorafenib for liver cancer: wrong stage, wrong doseRobin Kate Kelley
Gastroenterology & Hepatology|February 28, 2024
Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular CarcinomaRobin Kate Kelley
Journal of Gastrointestinal Oncology|August 9, 2019
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature reviewAudra N Boscoe, Catherine Rolland, Robin Kate Kelley
Clinical Liver Disease|April 1, 2020
Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular CarcinomaLaura A Huppert, John D Gordan, Robin Kate Kelley
Journal of Hepatology|January 20, 2020
Systemic therapies for intrahepatic cholangiocarcinomaRobin Kate Kelley, John Bridgewater, Gregory J Gores, et al.
Cancer Treatment Reviews|May 24, 2021
Cabozantinib: An evolving therapy for hepatocellular carcinomaAnthony B El-Khoueiry, Diana L Hanna, Josep Llovet, et al.
JAMA Ophthalmology|October 24, 2024
Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for CholangiocarcinomaIsabell Kassaye, Adam Alyafaie, Karen Zhang, et al.
Pageof 6